Chief GI Onc ; Director of clinical trials and clinical research solid tumors @Christianacare. Working to improve research in EOCRC. founding member @gutonclab
Joined May 2009
- Tweets523
- Following282
- Followers344
- Likes130
Deepak Vadehra retweeted
Hear ye hear ye!! New pembrolizumab TMB tumor-agnostic threshold is 13 rather than 10. 🔥
Our data suggests it is 16 mut/mb (best threshold)
Data coming soon!
Responses can be phenomenal. I have patients who went from “next step hospice” to “CR ongoing for years— aka cured”
Deepak Vadehra retweeted
Can’t believe we’re having a full session on KRAS G12D targeted therapy in pancreatic cancer! So glad to see how far we’ve come.
@DrShubhamPant @DAVAOnc @BaptistHealthSF @BHAcademics @MiamiCancerInst
Dr. @Sarbaji85064063 of @BaptistHealthSF discussed setidegrasib, a KRAS G12D-targeted degrader in pancreatic cancer, highlighting its mechanism, phase 1 efficacy and safety data, and ongoing phase 3 evaluation in first-line metastatic PDAC. #DAVAGI
I had a chance to read Matt‘s book and truly it hit home on so many levels. Congratulations @MatthewZachary I hope more people get a chance to read your book and the message resonates with them as it did with me.
HOLY. FUCKING. SHIT.
That is We the Patients in the front window of the flagship Barnes & Noble on Fifth Avenue in Manhattan.
Not tucked into Health & Wellness. Not spine-out on a shelf somewhere. THE WINDOW.
And then I walked inside and found another pile sitting on the Must-Read Nonfiction table.
I wrote We the Patients: Understanding, Navigating, and Surviving America’s Healthcare Nightmare after 30 years as a patient and 25 years professionally yelling about what this system does to actual human beings.
Somewhere between writing the damn thing, Wiley publishing it, the second printing, the third printing, the reviews, the emails from strangers, and watching this weird little patient uprising start finding its people, I apparently forgot that occasionally you get to stop and look around.
Today I looked around.
Fifth Avenue. Barnes & Noble. Front fucking window.
There are a lot of people who helped get this book from an idea rattling around in my head to that. And there are a lot of patients whose stories, anger, absurdities, heartbreak, and survival are inside those pages.
So I’m going to do something I’m historically terrible at and just take the fucking win.
Holy shit.
#WeThePatients #PatientAdvocacy #Healthcare
Deepak Vadehra retweeted
Thoughtful discussion of the role of SRS by Dr Prabhu for #brainmets - when and how? #BM #btsm @WakeCancer @AtriumHealthWFB @LevineCancer
A thoughtful piece from @MatthewZachary about the journey of patient advocacy and where it’s headed and rather where it needs to go.
thehill.com/opinion/healthca…
Deepak Vadehra retweeted
I Was In a Rut
I was in a rut, worn thin by the day,
frustration piled up in the ordinary way—
patients and paperwork, a job never done,
tired in my bones before the day was begun.
Deepak Vadehra retweeted
I was in a rut. I remember who I am,
I remember those I love, and those who give a damn,
the ones who call my name, those who shout—
I was in a rut, but this is my way out.
-- Manish
Deepak Vadehra retweeted
@NCCN please rapidly update the #pancreaticcancer guidelines.
Insurance company AI denying patients Daraxonrasib and recommending I try gem/erlotinib first. Probably because it remains on guidelines for a 2 week survival advantage! I hope the guidelines will consider removing
Deepak Vadehra retweeted
Kudos to @IowaMed MS4 Matthew Gao for leading this work describing outcomes in early-onset versus average-onset small bowel NETs using the SEER registry. More than a few studies (albeit all retrospective) now showing better outcomes in early-onset NETs (potentially better biology?), but a lot remains unknown still. This is an active area of research, work in progress.
Matt is applying for Internal Medicine residency this year and any program will be lucky to recruit a thoughtful, smart and driven future physician like him. @RPatel20166 @jason_semprini @michael_ororke @SethConcorsMD @ChandrikhaC @WinshipAtEmory @TheGutOncLab
Deepak Vadehra retweeted
⭐️Patient Education: New targeted pill for #PancreaticCancer
What #FDA approved #Daraxonrasib means for patients:
✅Median Overall Survival doubled
✅Oral pill
⚠️Rash, mouth sores,+diarrhea
#OncTwitter #GIOnc #gism #MedX
🔗Patient-friendly breakdown👇
oncupdates.com/article/a-new…
HUGE congrats to my brother @TimothyJBrown on this exciting chapter! Everyone knows his incredible accomplishments as a physician scientist, BUT he’s an even better friend, confidante, and human. A home run for @OncoJurdi @NateraOncology. Can’t wait to see the impact you make!
Pleased to announce as of next week that I will be joining @NateraOncology as a medical director in GI oncology.
I’m grateful for the 8 years at UTSW and the opportunity to grow as a GI oncologist. Looking forward to advancing the science of MRD and precision onc in GI cancers
Deepak Vadehra retweeted
Ivonescimab Plus Chemotherapy Demonstrates Statistically Significant Overall Survival Benefit Compared to Durvalumab Plus Chemotherapy in First-Line Advanced Biliary Tract Cancer in Single-Region Trial Conducted by Akeso in China
smmttx.com/news/press-releas…
Deepak Vadehra retweeted
Pleased to announce as of next week that I will be joining @NateraOncology as a medical director in GI oncology.
I’m grateful for the 8 years at UTSW and the opportunity to grow as a GI oncologist. Looking forward to advancing the science of MRD and precision onc in GI cancers
Deepak Vadehra retweeted
🚨New @US_FDA approval based off the #HERIZON-GEA-01 study analyzing #Zanidatamab in first line #HER2 positive mGEA
#OncTwitter #Oncology #gcsm #MedTwitter #MedX #HemOnc #FDA
Based off HERIZON-GEA-01, #Zanidatamab is now @US_FDA ✅ in 1L HER2+ mGEA:
⭐️PhIII, Zanidatamab + Chemo ± Tislelizumab vs. Trastuzumab + Chemo
- mPFS w/ Zani (±Tisle) 12.4 vs. 8.1mos
- mOS for triplet 26.4 vs. 19.2mos HR: 0.72
- ⬆️Diarrhea & Infusion reactions
#OncTwitter
Deepak Vadehra retweeted
Thrilled to share this work, now out in @JournalCancer
Expert consensus statement on the use of incretin mimetics in patients with NENs, eloquently summarized by @OncoThor in the tweet below. Grateful to be a part of this effort. This statement not only provides guidance/expert advice on tackling this challenge in clinic when seeing patients but also highlights the need for robust prospective evidence to guide future use of these agents. @NANETS1 @ENETS_ORG @WinshipAtEmory
Deepak Vadehra retweeted
Congratulations to Scott Siegel, Ph.D., MHCDS, on receiving the @DEBreastCancer 2026 Shining Light Award! 🎉
His research and advocacy are helping advance breast cancer prevention, early detection, and health equity across Delaware. ow.ly/h25J50ZB4QU
Deepak Vadehra retweeted
The @ASCO Living Guideline on Advanced Gastroesophageal Cancer is now published in @JCO_ASCO. Grateful to be included on the expert panel.
@MDmanishshah
@BHAcademics @MiamiCancerInst @OncBrothers @OncUpdates @oncodaily @Onco_Nexus
ascopubs.org/doi/10.1200/JCO…
Deepak Vadehra retweeted
I’m begging you to please let me review for you @NEJM. This never would’ve made it to press and you wouldn’t be getting cooked online
A new Clinical Practice article summarizes the classification, evaluation, risk stratification, and management of syncope. History, examination, electrocardiography, and orthostatic blood-pressure measurement identify the cause in most patients.
Read “Syncope” by Rose Anne Kenny, MD, DSc: nej.md/4cjFuVU
Ask AI Companion to provide a summary of this article for your patient. In Spanish.
ALT A flowchart from the Clinical Practice article "Syncope" by Rose Anne Kenny, M.D., D.Sc., that shows the general principles for initial evaluation of all patients after an episode of syncope. The chart includes steps such as suspected syncope, evaluation, history taking, and an ECG. It categorizes causes of syncope as certain or uncertain, leading to risk assessment and further evaluation or treatment.
Deepak Vadehra retweeted
Phase I/II expanded cohort study of liposomal CHK-1 inhibitor:
👉14 slots are available for patients with platinum resistant #ovarian #cancer (PROC)
👉17 slots are available for patients with #ANCSM (no limitation on # of prior lines).
Link: Study Details | NCT06526819 | SMP-3124LP in Adults With Advanced Solid Tumors | ClinicalTrials.gov
Pls contact if you have any questions:
#cancer #cancerresearch #progress @VUMCDiscoveries #ClinicalTrials @SumitomoCorpor1 @HPVAnalCancer @HPVAlliance @ABumRap
Deepak Vadehra retweeted
2/2: The future is ctDNA 2.0: serial monitoring integrated with multi-omics, imaging, clinical data, and AI-enabled interpretation. thelancet.com/journals/eclin…
@AzzaSarfraz @BrainTumorDoc @OncBrothers @oncodaily @OncoDailyGI @Onco_Nexus @OncUpdates
